Tablets: Each white round tablet (stamped "BRA200") contains 667 mg of calcium acetate, USP (anhydrous;Ca(CH3 COO) 2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and 10 mg of the inert binder, polyethylene glycol 8000 NF.
PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption.
Published Studies Related to Phoslo (Calcium Acetate)
Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial. [2011.11.30]
BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a marker of endothelial dysfunction and atherosclerotic complications in patients with chronic kidney disease (CKD). Because previous studies suggested that sevelamer may exert effects on FGF-23 level and endothelial function independently of its phosphate-lowering action, we tested the effect of sevelamer versus calcium acetate on vascular function and FGF-23 levels... CONCLUSIONS: In hyperphosphatemic patients with stage 4 CKD, treatment with phosphate lowering induces measurable improvements in flow-mediated vasodilatation. Furthermore, independently of serum phosphate level, FGF-23 level changes induced by phosphate binders are associated with simultaneous changes in flow-mediated vasodilatation. These observations are compatible with the hypothesis that FGF-23 may contribute to vascular dysfunction in this population. Copyright (c) 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease. [2011.02.16]
BACKGROUND: Hyperphosphatemia in patients with chronic kidney disease (CKD) contributes to secondary hyperparathyroidism, soft tissue calcification, and increased mortality risk. This trial was conducted to examine the efficacy and safety of calcium acetate in controlling serum phosphorus in pre-dialysis patients with CKD... CONCLUSIONS: In CKD patients not yet on dialysis, calcium acetate was effective in reducing serum phosphorus and iPTH over a 12 week period. TRIAL REGISTRATION: www.clinicaltrials.gov NCT00211978.
Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. 
BACKGROUND: Fibroblast growth factor 23 (FGF23) concentrations increase early in chronic kidney disease (CKD), and the influence of current CKD-mineral and bone disorder (MBD) therapies on serum FGF23 levels is still under investigation... CONCLUSIONS: Taken together, our results confirm that the current CKD-MBD therapies have an effect on serum levels of FGF23. Since FGF23 is emerging as a potential treatment target, our findings should be taken into account in the decision on how to manage CKD-MBD therapy. Copyright (c) 2010 S. Karger AG, Basel.
A randomized, double-blind, placebo-controlled trial of calcium acetate on serum
phosphorus concentrations in patients with advanced non-dialysis-dependent
chronic kidney disease. 
patients with CKD... CONCLUSIONS: In CKD patients not yet on dialysis, calcium acetate was effective
Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. [2010.12]
BACKGROUND: The relative effectiveness and safety of sevelamer, a mineral-free phosphate binder, for treatment of hyperphosphatemia in children with chronic kidney disease is uncertain. AIM: This study was designed to compare the efficacy and acceptability of sevelamer hydrochloride to calcium acetate as a phosphate binder in pediatric patients with chronic kidney disease... CONCLUSIONS: Compared to calcium acetate, use of sevelamer in children with chronic kidney disease is associated with similar reduction in serum phosphate levels, lower risk of hypercalcemia, and marked decrease in serum lipid levels.
Clinical Trials Related to Phoslo (Calcium Acetate)
CARE-2 (Calcium Acetate [PhosLoŽ]/Sevelamer[RenagelŽ] Evaluation Study 2) for Heart Calcification in Dialysis Patients [Completed]
The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and
sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive
technique, electron beam computed tomography (CT) scanning, to measure calcium in the
coronary arteries, the aortic valve, and the mitral valve.
EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) [Completed]
The purpose of this study is to determine if calcium acetate (PhosLo) can control serum
phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers [Recruiting]
To compare the bioequivalence of calcium acetate oral solution vs. calcium acetate gelcaps in
healthy volunteers with calcium citrate as a positive control.
Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients [Recruiting]
The purpose of this study is to demonstrate equivalence of calcium acetate oral solution and
sevelamer carbonate in maintaining serum phosphorus levels
This is a phase IV, multicenter, randomized, open-label, cross-over study to assess the
equivalence of a liquid formulation of a calcium-based phosphate binder, COS, to sevelamer
carbonate tablets, in hemodialysis dependent Chronic Kidney Disease subjects. The aim of
the study is to maintain serum phosphorus level and establish equivalence between COS and
sevelamer carbonate tablets.
Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4 [Recruiting]
Chronic kidney disease (CKD) patients often have high levels of a substance called
fibroblast growth factor-23 (FGF-23), a phosphorus excreting hormone, which has been related
to heart disease. As kidney function declines, less phosphorus is removed by the kidneys and
as a result phosphorus accumulates in the blood. In response to elevated phosphorus levels,
more FGF-23 is released to help facilitate the excretion of extra phosphorus into the urine.
In addition to effects on FGF-23, increased phosphorus levels can lead to calcification
(hardening) of the blood vessels in the CKD population.
Phosphate binding medicines are used in CKD patients to lower the amount of phosphorus
absorbed by the stomach and intestines after eating meals and snacks. In patients with CKD,
studies have shown that phosphate binders can lower FGF-23 levels in the blood. Lowering
FGF-23 levels in CKD patients may also lower substances in the blood that cause
calcification of blood vessels in the CKD population.
This study is being done to determine if using phosphate binders, either sevelamer
carbonate or calcium acetate, in the earlier stages kidney disease (before dialysis) can
decrease FGF-23 and biomarkers (substances in the blood) associated with hardening of the
blood vessels and heart disease.
Page last updated: 2013-02-10